CRISPR Therapeutics AG(CRSP US)
$54.11+2.645.13%
- Pricing and plans
Get the full experience
We save the real magic for signed-in users.
Get the full experience
We save the real magic for signed-in users.
| Millions USD (ex. Per Share) | FY201412/31/2014 | FY201512/31/2015 | FY201612/31/2016 | FY201712/31/2017 | FY201812/31/2018 | FY201912/31/2019 | FY202012/31/2020 | FY202112/31/2021 | FY202212/31/2022 | FY202312/31/2023 | FY202412/31/2024 | FY202512/31/2025 | Last 12M03/31/2026 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -153.6 | -366.3 | -581.6 | -568.5 | |||||||||||
| Depreciation & Amortization | 19.8 | 19.3 | 19.5 | 19.1 | |||||||||||
| Stock Based Compensation | 81.0 | 86.6 | 72.5 | 52.3 | |||||||||||
| Change in Working Capital | -193.6 | 156.3 | 71.9 | 1.6 | |||||||||||
| Other Non-Cash Items | -14.0 | -38.6 | 72.7 | 95.6 | |||||||||||
| Net Cash from Operating Activities | -260.4 | -142.8 | -345.0 | -400.0 | |||||||||||
| -Investments in Property, Plant & Equipment | -9.5 | -1.9 | -0.9 | -1.2 | |||||||||||
| -Acquisitions Net | - | - | - | - | |||||||||||
| -Purchases of Investments | -1,065.9 | -1,486.4 | -1,008.2 | -1,562.8 | |||||||||||
| Sales/Maturities of Investments | 1,452.5 | 1,207.8 | 1,011.3 | 1,166.3 | |||||||||||
| Other Investing Activities | -2.5 | - | -34.0 | -25.0 | |||||||||||
| Net Cash from Investing Activities | 374.6 | -280.5 | -31.8 | -422.8 | |||||||||||
| Net Debt Issuance | - | - | - | - | |||||||||||
| Net Stock Issuance | 62.7 | 300.7 | 426.0 | 988.7 | |||||||||||
| -Net Dividends Paid | - | - | - | - | |||||||||||
| Other Financing Activities | - | 31.3 | - | 18.7 | |||||||||||
| Net Cash from Financing Activities | 62.7 | 332.0 | 426.0 | 1,007.3 | |||||||||||
| Effect of Forex Changes | 0.7 | -0.0 | 0.1 | -3.7 | |||||||||||
| Net Change in Cash | 177.6 | -91.3 | 49.3 | 180.9 | |||||||||||
| Cash at End of Period | 389.5 | 309.8 | 359.1 | 1,277.9 | |||||||||||
| Operating Cash Flow | -260.4 | -142.8 | -345.0 | -400.0 | |||||||||||
| -Capital Expenditure | -9.5 | -1.9 | -0.9 | -1.2 | |||||||||||
| Free Cash Flow | -269.8 | -144.7 | -345.9 | -401.2 | |||||||||||